Synpha Biosciences is a biotechnology company developing synthetic phage therapeutics to treat various bacterial diseases. Leveraging proprietary technology and a machine learning AI platform, Synpha aims to overcome traditional challenges in phage therapy by creating advanced, targeted treatments.
Originating from the University of Wisconsin–Madison, the company is currently in the fundraising phase to advance its research and development efforts.
Synpha Biosciences technology includes:
- SynPhage™: An AI-patented platform that has algorithms that analyze phage-host interaction networks with the capability of predicting optimal phage modifications for enhanced efficacy.
